About Next Biomics

NextBiomics was born as a spin-off of the University of Naples FEDERICO II. The strength of NextBiomics is to convey expertise in the field of gastroenterology, pharmacology, genetics and molecular biology and a strong orientation towards the market and its needs.

Our mission is to develop intelligent drugs based not only on pharmacology but also on the use of data on the patient, his genetics and his microbiome. This is our idea of the medicine of the future with a strong centricity on the holistic vision of the patient.

Our patents

  1. “Galactosylated prodrugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug” Patent WO 2010/013279
  2. “Biological composition based on engineered lactobacillus paracasei subsp. paracasei F19 for the biosynthesis of cannabinoids” – Patent EP 3067058
  3. “Dietary methods using lactobacillus paracasei subsp. paracasei F19 as NAPE-PLD gene carrier for producing on demand Pea or Oea and relative biological dietary compositions thereof” . Patent EP 3040070
  4. Engineered E Coli Nissle 1927 expressing SARS CoV2 glicoprotein as a new immunization system against COVID19 infection.

Our Managing Team

Discover more about our management team

Giovanni Sarnelli, MD PhDCEO
Giovanni is professor of Gastroenterology at the University of Naples “Federico II”
He has a PhD in Digestive and Nutritional Pathophysiology from the 2nd University of Naples and a post doc from the University of Leuven (Belgium) where he enjoyed his research on gut-brain axis. Giovanni authored more than 100 research articles in international journals and is co-inventor of three international patents.
Walter Sanseverino, PhDManaging director
Walter is a passionate scientist and entrepreneur who is been devoted to democratize omics sciences to speed up their use in healthcare field. He is the founder of successful start-ups, holds a degree in biotechnology and a a PhD in Genomics. He counts with more than 40 high impact factor publications.
Giuseppe Esposito, PhDCTO
Giuseppe is an associate professor in Pharmacology and therapeutics and he is devoted to conception and development of innovative therapeutic tools for neurological and gastrointestinal diseases. He obtained his PhD in Science of Drugs in Naples, and after being a visiting scientist in Max Planck Institute of Munich (Germany) and BIDMC at Harvard Medical School of Boston (USA) he authored almost 80 articles and is currently group leader at Sapienza University of Rome.
Francesco Campobasso, BSCFO
With a great expertise in finance and accounting with a special focus on corporate assistance, audit and tax consultancy Francesco is chartered, accountant and statutory auditor. Member of the board of statutory auditors of entities and companies and currently advisor of Signoriello accounting firm.
Giovanni Esposito, MD PhDCSO
Prof. Esposito is Full Professor of Cardiology and Cardiovascular Fellowship Program Director at Federico II University of Naples; he is also Director of the Division of Cardiology of the Federico II University of Naples and President-elect of the Italian Society of Invasive Cardiology (SICI-GISE). He has received several awards for his contribution and commitment in the field of cardiology from national and international institutions and is being an experienced and trusted mentor for young cardiologists.

Our Advisors

More about our Advisors

Riccardo Aiese Cigliano, PhDScientist
With a PhD in biotechnology Riccardo is an expert in transfomation approaches, epigenetic regulation and chromatin remodelling, He holds a master?s in Biotechnological Sciences at the University of Naples ?Federico II? a bachelor?s in Biotechnological Sciences at the University of Naples ?Federico II? and an exensive portfolio of publications.
Jie Lu, MD PhDScientist
Jie Lu is professor at China Medical University with an extensive expertise in neurodevelopment, down syndrome, neural stem cell, neurodegeneration and gene therapy

Discover The Future

Committed to efficient precision medicine of cronic and infectious diseases through a new generation of probiotics.

Contact Us